Adamis Pharma Overview
Industry: Pharmaceuticals
Sector: Healthcare
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California. Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for Read MoreAdamis Pharma is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Adamis Pharma
Score